Usage and dosage of Lurbinectedin

Lurbinectedin (Lurbinectedin) usage and dosage often vary based on the patient's specific circumstances, type of condition, and doctor's recommendations. The following are general usage and dosage guidelines, but please note that these are for reference only and actual treatment plans should be developed by a medical professional:

1. Indications: Rubicatin is commonly used to treat recurrent small cell lung cancer (SCLC) and recurrent synovial sarcoma (Myxoid/round cell liposarcoma).

2. Method of administration: Rubicatin is usually given to patients via intravenous injection, which needs to be done in a medical institution or hospital. Injections are administered by a doctor or health care worker, as special training and equipment are required to ensure safety and effectiveness.

3. Dose: Rubicatin dosage is usually calculated based on the patient's weight and body surface area to ensure optimal therapeutic effect. The exact calculation and adjustment of dosage will be made by your doctor. Typically, the starting dose of rubicatin is 3.2 milligrams per millimeter (mg/m²) every three weeks.

4. Treatment cycle: Rubicatin treatment is usually carried out in a three-week cycle. A specific treatment plan will be developed by your doctor. Treatment may require multiple cycles until desired treatment goals are achieved or the disease progresses.

5. Medical monitoring: During treatment, patients need to undergo regular medical monitoring, including blood tests, electrocardiograms and other necessary examinations. This helps doctors evaluate treatment response and side effects and adjust treatment plans as needed.

6. Side effects management: Rubicatin treatment may be accompanied by a series of side effects, such as nausea, vomiting, fatigue, thrombocytopenia, leukopenia, etc. Patients should actively communicate with their doctors and report any side effects so that timely measures can be taken to manage and relieve discomfort.

7. Usage in special populations: The safety of rubicatin in pregnant women, lactating women and children has not been fully determined. When considering treatment, patients should inform their doctor whether they are pregnant, breastfeeding, or age appropriate for the use of this drug.

In short, the usage and dosage of Rubicatin should be formulated by the doctor based on the patient's specific situation and condition. Patients should work closely with medical professionals, follow their doctor's recommendations, and receive regular medical monitoring during treatment to ensure optimal treatment effectiveness and safety.

Rubicardin has not yet been launched in China, so it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase Rubicatin through overseas channels. There is only the original drug Rubicatin in foreign countries, and the price is relatively expensive. In comparison, the original drug in Singapore is slightly cheaper, priced at more than 30,000, and there are other American versions of the original drug, priced at more than 90,000.